

Britt Christensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6580908/publications.pdf>

Version: 2024-02-01

52
papers

1,137
citations

516710

16
h-index

395702

33
g-index

53
all docs

53
docs citations

53
times ranked

1498
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. <i>Gastroenterology</i> , 2020, 159, 6-13.e6.	1.3	185
2	Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1557-1564.e1.	4.4	157
3	Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 54-72.	3.7	93
4	Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 609-616.	1.3	83
5	Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 486-493.	4.4	76
6	Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2518-2525.e1.	4.4	64
7	Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 753-762.	3.7	63
8	Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 554-580.	1.3	43
9	Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 873-886.	3.7	43
10	Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1551-1562.	3.7	38
11	Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 637-643.	3.7	37
12	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 849-860.	1.9	34
13	Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1438-1439.	3.7	31
14	Gastrointestinal ACE2, COVID-19 and IBD: Opportunity in the Face of Tragedy?. <i>Gastroenterology</i> , 2020, 159, 1623-1624.e3.	1.3	21
15	Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 318-331.	8.1	20
16	Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S769-S773.	1.3	17
17	Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 84-94.	3.7	17
18	Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 6-27.	3.7	17

#	ARTICLE	IF	CITATIONS
19	Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty. <i>Internal Medicine Journal</i> , 2020, 50, 798-804.	0.8	12
20	Review article: investigation and management of internal fistulae in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1064-1079.	3.7	10
21	Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1345-1353.	1.3	9
22	A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to Conceive. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1909-1918.	1.9	9
23	Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 553-559.	1.9	9
24	SARS-CoV-2 vaccination in patients with inflammatory bowel disease. <i>GastroHep</i> , 2021, 3, 212-228.	0.6	7
25	Tu1350 Vedolizumab in the Treatment of IBD: The University of Chicago Experience. <i>Gastroenterology</i> , 2015, 148, S-866.	1.3	5
26	Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1423-1424.	3.7	5
27	Follow-Up of Patients With Ulcerative Colitis and Histological Normalization. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 987-988.e1.	4.4	4
28	Evaluation and management of rectal bleeding in pregnancy. <i>Medical Journal of Australia</i> , 2021, 215, 377-382.	1.7	4
29	P176 Expert consensus on acquisition and reporting of intestinal ultrasonography activity in Crohn's disease. A prospective inter-rater agreement study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S225-S226.	1.3	3
30	Managing COVID-19 in patients with inflammatory bowel disease: navigating unprecedented challenges. <i>Internal Medicine Journal</i> , 2021, 51, 284-287.	0.8	3
31	Self-Reported Failure to Address Sexual Function in Patients With Inflammatory Bowel Disease by Gastroenterologists: Barriers and Areas for Improvement. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1465-1468.	1.9	3
32	P300 Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. The STRIDENT Randomised Controlled Trial. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S328-S330.	1.3	2
33	Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1422-1423.	3.7	2
34	P092 Humoral and T cell responses to COVID-19 vaccination in IBD. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i190-i191.	1.3	2
35	P695 Attitudes and predictors of COVID-19 vaccine uptake in patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i593-i594.	1.3	2
36	Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 178-179.	3.7	1

#	ARTICLE	IF	CITATIONS
37	Cough in the Immunosuppressed Patient. <i>Gastroenterology</i> , 2019, 156, e3-e4.	1.3	1
38	Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1796-1796.	1.3	1
39	P445 Efficacy and safety of induction therapy with calcineurin inhibitors followed by maintenance therapy with vedolizumab in severe ulcerative colitis: a large patient cohort with long-term follow-up. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S401-S401.	1.3	1
40	Letter: IBD nurseâ€™ pivotal role in the time of the pandemic. Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 746-747.	3.7	1
41	Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapyâ€™checkpoint inhibitor colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 636-637.	3.7	1
42	Treat to transmural healing: how to incorporate intestinal ultrasound into the treatment of inflammatory bowel disease. <i>British Journal of Radiology</i> , 2022, 95, .	2.2	1
43	Editorial: international consensus in clinical trial endâ€™points in ulcerative colitis â€™ clarity or just a step in clearing the fog?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1274-1275.	3.7	0
44	Letter: is pneumococcal vaccination safe during the COVIDâ€™19 pandemic? Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 921-922.	3.7	0
45	Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice.. <i>Digestive and Liver Disease</i> , 2020, 52, 1250-1251.	0.9	0
46	P628 Histological remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S519-S520.	1.3	0
47	Altered bowel habit and rectal bleeding in pregnancy: the importance of recognising undiagnosed inflammatory bowel disease. <i>Internal Medicine Journal</i> , 2021, 51, 424-427.	0.8	0
48	Endoscopic and histologic endpoints as treatment targets: Are we there yet?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 8-9.	2.8	0
49	DOP10 Persistent sonographic Inflammation as a predictor of clinical complications in patients with Crohnâ€™s Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S048-S049.	1.3	0
50	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2452-2454.	4.4	0
51	Letter: Covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1416-1417.	3.7	0
52	Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 766-767.	3.7	0